Medical - Diagnostics & Research · NYSE
Current Price
$669.54
PE Ratio (TTM)
35.3x
Intrinsic Value
$774.99
+13.6% margin of safety
COMPETITIVE MOAT
↑Dominant Scale and Breadth
Thermo Fisher's vast product portfolio and global reach create significant scale advantages. This allows for cost efficiencies and a comprehensive offering that is difficult for smaller competitors to replicate.
↑Ecosystem Lock-in and Switching Costs
Customers rely on Thermo Fisher's integrated workflow solutions, from research to diagnostics. This creates high switching costs as changing vendors disrupts established processes and requires significant investment.
↑Brand Reputation and Trust
The company's long-standing reputation for quality and reliability in critical scientific and healthcare applications fosters deep customer trust. This brand equity is a significant barrier to entry for new players.
INVESTMENT RISKS
↓Integration Challenges of Acquisitions
Thermo Fisher frequently acquires companies to expand its offerings. Integrating these diverse businesses can be complex and may not always yield the expected synergies or growth.
↓Dependence on Key Supplier Relationships
The company relies on a complex supply chain for its diverse product lines. Disruptions or increased costs from critical suppliers could impact production and profitability.
↓Valuation Concerns and Market Sentiment
Recent analyses suggest Thermo Fisher may be trading at a premium valuation. Any slowdown in growth or negative market sentiment could lead to significant stock price corrections.
Base case
A base case PE valuation for TMO estimates a fair value of about $774.99 per share, against a current price of $669.54. The model assumes 10.3% annual earnings growth, a 34.98x target PE multiple, and a 10% discount rate.
Intrinsic Value
$774.99
Margin of safety
+13.6%
Expected annual return
+3.0%
Base case assumptions: 10.3% annual earnings growth, 34.98x target PE, 10% discount rate, 5 year projection. Data as of 2026-11-20.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Thermo Fisher Scientific Inc. respond.
Open PE Calculator for TMOThermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
PE Ratio (TTM)
35.3x
PEG Ratio
3.71
Earnings Yield
2.86%
ROE (TTM)
13.3%
Revenue/Share (TTM)
$127.98
Dividend Yield
0.27%
Debt/Equity
0.76x
The trailing twelve-month PE ratio of TMO reflects how much investors pay per dollar of Thermo Fisher Scientific Inc.'s earnings. This metric is most useful when compared to Medical - Diagnostics & Research peers and the company's own historical range.
TMO's PE of 35.3x combined with a PEG ratio of 3.71 provides a growth-adjusted perspective. A PEG above 2.0 means the P/E is high relative to the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Medical - Diagnostics & Research, a DCF analysis may be more appropriate.
To value Thermo Fisher Scientific Inc. using PE: (1) Compare the current PE (35.3x) against the Medical - Diagnostics & Research median to assess relative pricing, (2) check the PEG ratio (3.71) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
TMO's PEG ratio is 3.71, calculated by dividing the PE ratio (35.3x) by the expected earnings growth rate. A PEG above 2.0 means the P/E is high relative to the expected earnings growth rate. Note that PEG accuracy depends on the reliability of growth estimates.
PE ratio gives a quick relative read — how TMO is priced versus Medical - Diagnostics & Research peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
P/E and DCF value TMO with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.